Sorry, I don't understand your search. ×
Back to Search Start Over

FRI0566 Attributes of The Subcutaneous Biologic Therapy Preferred by Patients with Rheumatic Disease and Satisfaction with The Treatment. RHEU LIFE Survey

FRI0566 Attributes of The Subcutaneous Biologic Therapy Preferred by Patients with Rheumatic Disease and Satisfaction with The Treatment. RHEU LIFE Survey

Authors :
Loreto Carmona
Enrique Batlle
F.J. De Toro
Carlos M. González
María J. Arteaga
Saturnino Fernández
Luis Cea-Calvo
Source :
Annals of the Rheumatic Diseases. 75:646.1-646
Publication Year :
2016
Publisher :
BMJ, 2016.

Abstract

Background Preferences of patients and satisfaction with the medication are important to improve adherence and outcomes. Objectives In patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA) and psoriatic arthritis (PsA), we explored the attributes of drugs preferred by them, and the degree of satisfaction with the current medication. Methods RHEU-LIFE was a survey to patients >18 years-old with RA axial SpA or PsA treated with subcutaneous (SC) biological drugs, from 50 outpatient rheumatology hospital clinics. Patients responded anonymously to the survey. They ranked 5 treatment attributes from 1 (the most important) to 5 (the least important), and expressed their satisfaction with each one from “very satisfied” to “very dissatisfied”. Results The survey was given to 1000 patients, 592 responded (59.2%, mean age 51.7 years, 42.4% men and 57.6% women; underlying disease RA: 304 (54.2%), axial SpA: 141 (25.1%), PsA: 116 (20.7%), not identified: 31. The biological drug was first (60.4%), second (26.8%) and third or more (13.5%). The attributes mentioned most frequently as “the most important” were normalization of quality of life (QoL) and symptoms control (43.6% and 32.5%, table). The importance was similar in patients with different diseases or treated with first, second or third biologic. The percentage “satisfied” or “very satisfied” was high for every attribute (80% or higher, table) and similar between patients with different conditions. The percentage “satisfied” or “very satisfied” with symptoms control and normalization of QoL was greater in those receiving the first biologic (87.8% and 85.7%) and lower with the third or more (78.4% and 72.0%, both p Conclusions Patients with rheumatic diseases treated with SC biological drugs give more importance to normalization of the quality of life and symptom control than to tolerability, speed of action and the comfort or easeness of use, and express a high degree of satisfaction with their current treatment, especially those receiving therapy with a first biologic. Acknowledgement Financed by Merck Sharp & Dohme of Spain and endorsed by the patients9 association ConArtritis (Arthritis National Coordinator). Disclosure of Interest None declared

Details

ISSN :
14682060 and 00034967
Volume :
75
Database :
OpenAIRE
Journal :
Annals of the Rheumatic Diseases
Accession number :
edsair.doi...........1f54a9cb3d3b2716d35b19c811c03a1d
Full Text :
https://doi.org/10.1136/annrheumdis-2016-eular.3569